Oxindole Derivatives as Multi‐Target Agents for Alzheimer's Disease: A Promising Therapeutic Strategy

Abstract

Alzheimer's disease (AD) is a multifactorial neurological disorder having a complex pathology that may progress and worsen over time. Several research teams across the world are exploring the new advancements in the area of AD. There exist numerous FDA‐approved medications for AD; however, they have certain limitations, like they just slow down the progression of the disease, but do not completely cure the disease and focus on one‐drug one‐target approaches. However, there is an urgent need for a one‐drug multiple‐target approach. A partial inhibition of multiple pathways is far better than complete inhibition of a single pathway to obtain an effective result. Various polyfunctional heterocyclic scaffolds can target multiple pathways, also termed as privileged substructures. Oxindole has emerged as a prominent and well‐known scaffold nowadays due to its diversified pharmacological activities. This review will give a thorough and sound knowledge about the advancements in oxindole analogs for AD, which will help the various research groups to design, synthesize, formulate, and evaluate potential oxindoles as a lead for clinical practices.